Stock Analysis, Dividends, Split History

SBOT / Stellar Biotechnologies Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price1.37
Volume128,300.00
Market Cap ($M)7.36
Enterprise Value ($M)1.54
Book Value ($M)12.39
Book Value / Share2.32
Price / Book0.62
NCAV ($M)11.22
NCAV / Share2.10
Price / NCAV0.66
Share Statistics
Common Stock Shares Outstanding 10,520,096
Common Shares Outstanding 10,520,096
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.68
Return on Assets (ROA)-0.39
Return on Equity (ROE)-0.41
Balance Sheet (mrq) ($M)
Assets12.80
Liabilities0.41
Quick Ratio27.49
Current Ratio28.06
Income Statement (mra) ($M)
Contracts Revenue50,000.00
Sales Revenue Goods Net178,287.00
Revenue From Grants0.00
Revenues228,287.00
Operating Income-5.22
Net Income-5.03
Earnings Per Share Basic And Diluted-0.49
Earnings Per Share Diluted-0.49
Earnings Per Share Basic-0.49
Cash Flow Statement (mra) ($M)
Cash From Operations-4.70
Cash from Investing1.69
Cash from Financing1.69
Identifiers and Descriptors
CUSIP85855A203
Central Index Key (CIK)1540159
Related CUSIPS
85855A104

Split History

Stock splits are used by Stellar Biotechnologies Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related News Stories

The Risks Of Small Cap Momentum Stocks

2018-07-25 seekingalpha
I’m sure you have all been warned, investing in small cap stocks is akin to gambling. Sometimes you come out on top, while at times you can lose a significant portion of investment. Don’t get me wrong, there are many small caps out there that offer great potential. However, there are significant risks involved. (0-1)

Your Daily Pharma Scoop: Exelixis Publishes Positive Data, Stellar Trial Succeeds, Kalytera's Pre-IND Meet

2018-07-07 seekingalpha
Exelixis (EXEL) announced results from the Phase 3 clinical trial of Cabometyx (cabozantinib) in treatment-experienced patients with hepatocellular carcinoma (‘HCC). The results were published in the New England Journal of Medicine (‘NEJM). Median overall survival (‘OS) showed statistically significant improvement over placebo. OS for Cabometyx was 10.2 months while that for placebo was 8 months. Median progression-free survival (‘PFS) too showed significant improvement. (19-0)

BRIEF-Stellar Biotechnologies Reports Q2 Loss Per Share Of $0.90

2018-05-07 reuters
* STELLAR BIOTECHNOLOGIES - AT MARCH 31, 2018, CO HAD WORKING CAPITAL OF $3.7 MILLION; CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $3.8 MILLION (3-3)

Bright Lights On Capitalist Woodstock, Tech Developers And Sports Betting

2018-05-05 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (973-3)

BRIEF-Stellar Biotechnologies Announces One-For-Seven Reverse Split

2018-04-27 reuters
* STELLAR BIOTECHNOLOGIES INC - ANTICIPATES THAT REVERSE SHARE SPLIT WILL BECOME EFFECTIVE AT 4:00 P.M. EASTERN TIME ON MAY 4, 2018 Source text for Eikon: Further company coverage: (3-3)

CUSIP: 85855A203